Target hits a new high after a fantastic 3rd-quarter report. Bill Mann reflects on the leadership of Target CEO Brian Cornell and shares why he thinks Target is still a buy at this price. Plus, we discuss Lowe’s latest results, the upcoming IPO of Saudi Aramco, and the precise location of America’s Midwest. (To get 50% off our flagship Stock Advisor service, go to www.StockIdeas.Fool.com.) Thanks to Audible for supporting The Motley Fool Podcasts. For a limited time, get 3 months of Audible for $6.95 a month at www.audible.com/Fool or text FOOL to 500500.
Amarin's shares rocketed higher after a key FDA committee recommended expanding the label of its triglycerides lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics and partner Vertex Pharmaceuticals are also soaring following the release of interim, early-stage results for its gene-editing therapy for beta thalassemia and sickle cell disease therapy. Stocks: AMRN, CRSP, VRTX
Is it better to be a generalist or a specialist? Can you ever have too much grit? And what do birds and frogs have to do with business success? On this week’s show, we revisit our conversation with David Epstein, author of the New York Times bestseller Range: Why Generalists Triumph in a Specialized World.
Emily Flippen is back to help us review a handful of 5-Stock Samplers from the last few years. And it's time to close the books on one of those samplers, but don't let that stop you from owning these stocks for years or decades to come.
Thanks to Audible for supporting The Motley Fool Podcasts. For a limited time, get 3 months of Audible for $6.95 a month at audible.com/FOOL or text FOOL to 500500.